Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows by Cassone, Giulia et al.
Journal of
Clinical Medicine
Review
Treatment of Rheumatoid Arthritis-Associated
Interstitial Lung Disease: Lights and Shadows
Giulia Cassone 1,2 , Andreina Manfredi 3, Caterina Vacchi 4, Fabrizio Luppi 5 ,
Francesca Coppi 6, Carlo Salvarani 3 and Marco Sebastiani 3,*
1 Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41124 Modena,
Italy; giulia.cassone@unimore.it
2 Rheumatology Unit, IRCCS Arcispedale Santa Maria Nuova, Azienda Unità Sanitaria Locale-IRCCS di
Reggio Emilia, 42100 Reggio Emilia, Italy
3 Chair and Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria
Policlinico di Modena, 41124 Modena, Italy; andreina.manfredi@gmail.com (A.M.);
carlo.salvarani@ausl.re.it (C.S.)
4 Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41124 Modena,
Italy; caterina.vacchi@unimore.it
5 Respiratory Unit, University of Milano Bicocca, S. Gerardo Hospital, 20900 Monza, Italy;
fabrizio.luppi@unimib.it
6 Department of Cardiology, University of Modena and Reggio Emilia, Azienda Ospedaliero-Univesitaria
Policlinico di Modena, 41124 Modena, Italy; coppi.francesca@aou.mo.it
* Correspondence: marco.sebastiani@unimore.it; Tel.: +39-059-4225636; Fax: +39-059-4223007
Received: 11 March 2020; Accepted: 3 April 2020; Published: 10 April 2020


Abstract: Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5–1%
of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary complication of RA
and it is responsible for 10–20% of mortality, with a mean survival of 5–8 years. However, nowadays
there are no therapeutic recommendations for the treatment of RA-ILD. Therapeutic options for
RA-ILD are complicated by the possible pulmonary toxicity of many disease modifying anti-rheumatic
drugs (DMARDs) and by their unclear efficacy on pulmonary disease. Therefore, joint and lung
involvement should be evaluated independently of each other for treatment purposes. On the other
hand, some similarities between RA-ILD and idiopathic pulmonary fibrosis and the results of the
recent INBIULD trial suggest a possible future role for antifibrotic agents. From this perspective,
we review the current literature describing the pulmonary effects of drugs (immunosuppressants,
conventional, biological and target synthetic DMARDs and antifibrotic agents) in patients with RA
and ILD. In addition, we suggest a framework for the management of RA-ILD patients and outline a
research agenda to fill the gaps in knowledge about this challenging patient cohort.
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1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting 0.5–1% of the population
worldwide [1]. It is characterized by symmetrical erosive synovitis and progressive disability, often
complicated by extra-articular manifestations. Among them, lung involvement is common, and it
can include a wide spectrum of disorders, ranging from airways and pleural disease, bronchiectasis,
and nodules, to infection and drug toxicity (Table 1) [2–4].
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Table 1. Lung involvement in Rheumatoid Arthritis.
Interstitial lung disease
UIP
NSIP, OP, DIP, LIP, mixed disease
Airways disease
Bronchiectasis
Bronchiolitis
Bronchiolitis obliterans
Follicular bronchiolitis
Panbronchiolitis
Chronic small airway obstruction
Cricoarytenoid arthritis
Rheumatoid nodules
generally, in subpleural areas, single or multiple, solid or cavitary, range in size
Pleural disease
Pleuritis
Pleural effusion
Pleural thickening
Lung entrapment and trapped lung
Pneumothorax
Vascular disease
Pulmonary hypertension
Primary (related to underlying vasculitis)
Secondary (associated to ILD)
Vasculitis
Haemorrhagic alveolitis
Venous thromboembolism
Caplan syndrome
it occurs in patients with both RA and pneumoconiosis
Lower respiratory tract infection
Common bacterial
Opportunistic infection (pneumocystis jirovecii)
Fungal
Mycobacterial
Amyloidosis
Apical fibrobullous disease
Lung cancer
Drug toxicity
Nsaids
Diffuse pulmonary infiltration
Eosinophilic pneumonia
ARDS
Bronchospasm
Infection/Pneumonitis
Noncardiogenic pulmonary edema
Glucocorticoids
Infection/Pneumonitis
Cyclophosphamide and
Mycophenolate mofetil Infection/Pneumonitis
Fibrosis
Noncardiogenic pulmonary edema
Methotrexate
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Table 1. Cont.
Hypersensitivity pneumonitis
Infection
New onset or exacerbation of ILD
Noncardiogenic pulmonary edema
Bronchospasm
Leflunomide
Hypersensitivity pneumonitis
Infection
New onset or exacerbation of ILD
Other conventional DMARDs
Infection/Pneumonitis
Obliterative bronchiolitis
New onset or exacerbation of ILD
Drug-induced lupus
Biologic DMARDs
Infection/Pneumonitis
Noncardiogenic pulmonary edema
New onset or exacerbation of ILD
Drug-induced lupus
Interstitial lung disease (ILD) is a serious pulmonary complication in RA, with a negative impact
on overall prognosis and utilization of healthcare resources [5–8]. About 10% of the RA patients
develop a clinically significant ILD that is responsible for 10–20% of mortality, with a mean survival
of 5–8 years [5–8]. However, the real incidence of RA-related ILD (RA-ILD) is still unknown, and a
variable prevalence has been reported in the literature [5–8]. The usual interstitial pneumonia (UIP) is
the predominant histological/radiological pattern of RA-ILD, reported in up to 66% of cases [9–19]
(Table 2). ILD can occur at any point in the natural history of RA, sometimes before the appearance of
joint involvement [14,20,21]. Since its clinical manifestations usually appear in the advanced stages of
lung disease, early diagnosis of RA-ILD is challenging.
Table 2. Histologic classification and typical features of idiopathic interstitial pneumonia,.applicable to
rheumatoid arthritis RA-ILD interstitial lung disease [9–19].
Histologic Pattern Prevalence in RA Pattern of Distribution Radiographic Findings
UIP: Usual interstitial
pneumonia 8–66%
Peripheral, subpleural,
basal
Reticular opacities; honeycombing;
minimal ground-glass opacity;
architectural distortion
NSIP: Nonspecific
interstitial pneumonia 19–57%
Peripheral, basal,
symmetric
Extensive ground-glass opacity; irregular
linear opacities; traction bronchiectasis;
subpleural preservation
RB: Respiratory
bronchiolitis 0–42%
Principally upper fields,
centrilobular
Bronchial wall thickening; centrilobular
nodules; ground-glass opacities
Mixed forms and
unclassifiable interstitial
pneumonia
0–11% Coexisting patterns of interstitial fibrosingand other lung disease, e.g., emphysema
OP: Organizing
pneumonia 0–11%
Subpleural,
peribronchial
Focal ground-glass opacities;
consolidations; reversed halo sign
DAD: Diffuse
alveolar damage 0–11% Diffuse or focal
Consolidations; ground-glass opacities;
traction bronchiectasis
DIP: Desquamative
interstitial pneumonia rare
Lower fields,
predominantly
peripheral
Ground-glass attenuation; cysts;
reticular opacities
LIP: Lymphoid
interstitial pneumonia rare
Predominantly in the
upper lung fields
Thin-walled cysts; centrilobular nodules;
ground-glass attenuation;
peribronchovascular septal thickening
PPFE: Idiopathic
pleuroparenchymal
fibroelastosis
rare Peripheral, upper fields Pleural thickening; subpleuralfibrotic changes
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Moreover, in patients with non-symptomatic RA-ILD, a clinical, functional and radiologic
follow-up of the lung is mandatory to identify patients with progressive disease.
In fact, the progression and the severity of lung involvement are the two main factors to consider
when decision-making on treatment is needed. Histopathologic/radiologic pattern also plays a pivotal
role. High-resolution computed tomography (HRCT) showed a high correlation with the histologic
pattern, especially in UIP subtypes, therefore, it is now considered the gold-standard for the diagnosis
and a lung biopsy is performed in doubtful cases only [22]. However, HRCT can sometimes fail to
correctly identify the pulmonary pattern in clinical practice, since it lacks to show both some pathologic
findings such as lymphoid hyperplasia and peribronchiolar lesions and overlap UIP and non-UIP
patterns [23–25].
The decision to start treatment is also influenced by a patient′s age, gender, the worsening of
symptoms or pulmonary function tests (PFTs), and the presence of comorbidities that might increase
the risk of adverse events (diabetes mellitus, osteoporosis, etc.) [20,21,26–32]. Moreover, recent studies
showed that some radiological HRCT findings such as honeycombing, correlate with a poor prognosis,
but the role of the ILD pattern in the therapeutic choice is still uncertain [23,33].
The therapeutic approach to RA-ILD patients is further complicated by some unresolved matters.
First, both conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) have been
implicated in the development of drug-related pulmonary toxicity with conflicting data (Table 1; drug
toxicity) [21,28,33–36]; secondly, there is no evidence that the treatment of RA could be effective also
on lung involvement. On the contrary, immunosuppressive drugs employed in connective tissue
diseases (CTD) or antifibrotic drugs approved for idiopathic pulmonary fibrosis (IPF) are not effective
on arthritis.
Summarizing, to treat ILD secondary to RA is not the same as treating RA in patients with
concomitant ILD.
In the absence of controlled studies, the therapeutic approach to RA-ILD is still debated and
based on empirical approaches dependent on retrospective studies and case series. Several therapeutic
agents have been suggested, but nowadays there are no therapeutic recommendations for the treatment
of RA-ILD.
The latest American College of Rheumatology (ACR) and European League Against Rheumatism
(EULAR) guidelines for the management of RA do not specifically consider patients with RA-ILD,
suggesting the need for a multidisciplinary approach [37,38], while the National Institute for
Health and Care Excellence (NICE) and Spanish Society of Rheumatology have proposed national
recommendations, suggesting the use of abatacept and rituximab in patients with RA-ILD, and advising
against the use of TNF inhibitors [39,40].
Due to the absence of evidence for RA-ILD treatment and its potential adverse effects, the decision
to treat should be based on the balance between its benefits and the burden of the disease in every
single patient. In asymptomatic patients with non-progressive ILD, a “wait and see” approach is
usually recommended [26–28].
From this perspective, we review the current literature on the treatment of patients with
RA-associated ILD and discuss the unsolved problems regarding this challenging patient cohort.
To achieve our purpose, we reviewed the published studies describing the pulmonary effects of
drugs (immunosuppressants, conventional, biological and target synthetic DMARDs and antifibrotic
agents) in patients with RA and ILD, focusing on the articles where lung involvement was
specifically investigated.
Additionally, we suggest a framework for the management of RA-ILD and outline a research
agenda to fill the gaps in our knowledge in this field.
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2. Immunosuppressants
The Panther study demonstrated an increase in mortality and infections in patients with IPF
treated with immunosuppressive drugs [41]. The role of immunosuppressants in usual interstitial
pneumonia (UIP) in RA or CTD has not been clarified, but a better response in ILD patterns different to
UIP has been suggested by some retrospective studies [42–44].
Therefore, RA-ILD with nonspecific interstitial pneumonia (NSIP) or organizing pneumonia
(OP) patterns could have a more favorable response to immunosuppressive therapy than the UIP
pattern [42–44].
However, some patients have unclassifiable or mixed patterns in HRCT, and a lung biopsy can also
identify various histologic findings in different specimens. Unluckily, no data clarify the treatment’s
response and the progression of the disease over time in these patients [45].
2.1. Corticosteroids
The effect of corticosteroids on patients with UIP pattern remains unclear. In the retrospective study
by Song et al., 50% of 84 patients with UIP pattern treated with corticosteroids and immunosuppressants
presented improvement or stabilization of lung function, but without significant differences with the
untreated group [46]. Moreover, among 10 RA-ILD patients with UIP pattern, Lee et al. described the
improvement of lung function in two patients and stability in three of them during a median follow-up
of 4.2 years [47].
In a recent retrospective case series including 11 RA patients, therapy with pulse intravenous
methylprednisolone followed by oral prednisone and tacrolimus appeared to be effective and
well-tolerated [48].
On the other hand, corticosteroids increased the risk of serious infections in patients with RA-ILD.
Zamora-Legoff found that a mean daily dose of prednisone higher than 10 mg was associated with a
higher rate of infections, despite the combination with DMARDs [49].
In our cohort of RA patients, respiratory infections were associated with ILD, steroids, and the
use of biologic DMARDs (bDMARDs). Among 33 patients with ILD, combination-therapy with
b-DMARDs, methotrexate, and corticosteroids was significantly more frequently recorded in patients
with infections [50].
2.2. Cyclophosphamide and Mycophenolate Mofetil
Cyclophosphamide (CYC) demonstrated a modest advantage in systemic sclerosis-related ILD
(SSc-ILD) and other CTD-ILD [50–54], especially in combination with methylprednisolone pulses,
although a metanalysis doubted the efficacy of CYC in SSc-related lung fibrosis [55].
There are no controlled clinical trials for CYC in RA-ILD, but it is used in clinical practice despite
its limited efficacy data [46,56–59], especially in the case of rapidly progressive ILD. Recently, a Chinese
retrospective study analyzed the factors associated with progression and survival in 266 RA-ILD
patients, observing a better survival in the group treated with CYC [60].
Since CYC shows little benefit on RA joint involvement, it is usually associated with corticosteroids
or other immunosuppressants [46,56–60].
Mycophenolate mofetil (MMF) is considered the main alternative to CYC as a first-line agent or a
possible maintenance therapy in CTD-ILD, with a lower rate of side effects than CYC [56,61–63].
No studies directly compare these two drugs in RA-ILD patients, as well as no data being available
to recommend MMF in RA-ILD. Saketkoo et al. described a clinical improvement and stability of
functional and radiological lung assessment in a small case series of 3 RA-ILD patients [63]. In another
retrospective study, MMF induced the stability of forced vital capacity (FVC) and the diffusing capacity
of the lungs for carbon monoxide (DLCO) [62].
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In 2016, a retrospective study from the UK found better survival in patients treated with MMF than
azathioprine (AZA). The relative risk of death for any cause was increased for patients on prednisone,
unaltered for AZA, and decreased for MMF. The Authors suggested a better outcome with MMF rather
than CS or AZA for the treatment of RA-ILD [64]. Unlikely, both CYC and MMF are ineffective for the
articular manifestations of the disease.
3. Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs)
Disease-modifying antirheumatic drugs, both conventional (cDMARDs) and biologic (bDMARDs),
have been demonstrated to improve the joint involvement of RA, but their impact on extra-articular
manifestations of the disease, mainly ILD, is unclear. Case reports, case series, and data from registries
or retrospective studies demonstrated a wide spectrum of pulmonary effects (Table 1; drug toxicity),
including improvement, but also the development and worsening of ILD [34,46,65,66].
Only a few reports describe the use of cDMARDs as a treatment for ILD in patients with RA
(Table 3).
3.1. Methotrexate
Methotrexate (MTX) has been associated with acute hypersensitivity pneumonia and with chronic
ILD. However, recent studies and meta-analyses suggested that MTX-hypersensitivity pneumonia is
less common than previously thought, and interestingly, no episodes of MTX related hypersensitivity
pneumonia have been recorded in controlled trials after 2001 [67]. Moreover, the association between
MTX and ILD development has been recently questioned [5,67–70].
Kiely described data by ERAN and ERAS registries, showing no increased risk of ILD in RA
patients treated with MTX; even better, exposure to MTX was associated with a significantly reduced
risk of incident RA-ILD [70].
In 2014, a meta-analysis including 8584 participants from 22 double-blind, randomized, controlled
trials demonstrated an increased risk of total adverse respiratory events relative to comparator agents.
In particular, MTX was associated with an increased risk of total infectious adverse respiratory events,
but not with noninfectious respiratory adverse events, including ILD and MTX-related pneumonitis [71].
Finally, Rojas-Serrano has recently observed a longer survival in RA-ILD patients treated with MTX
compared to other cDMARDs [72].
One paper by the same Authors describes the use of MTX and leflunomide (LEF) for the treatment
of ILD in 40 RA patients. Patients received prednisone 1 mg/kg/day associated with MTX in 18 patients
and LEF or AZA, or both, in 22. After a 4-month follow-up, FVC improved in both groups [65].
Although recent studies questioned the role of MTX as a causative agent in lung involvement [67–72],
it may be appropriate to conduct tight monitoring of lung function in patients with an established
diagnosis of ILD in treatment with MTX [72,73]. However, MTX remains one of the central drugs in the
treat-to-target approach to RA, so treatment should not be delayed or limited in active and progressive
RA [37].
3.2. Leflunomide
Leflunomide has been associated with rapid onset hypersensitivity pneumonia and new-onset or
progression of pre-existing ILD, with discordant published data.
In a Japanese cohort, 1.2% of 5054 RA patients who received LEF had a new-onset and/or
exacerbation of ILD. Pre-existing ILD was the most important risk factor for LEF-induced ILD [74].
Similar results were achieved by Ju et al. in 1010 Korean patients, but no deaths due to ILD were
detected [75].
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In 2006, Suissa reported an increased risk of worsening or new onset of ILD with LEF, but only in
patients with previous use of MTX or preexisting ILD [76].
Two systematic reviews found conflicting results. Conway et al. showed no association between
LEF and increased risk of total or infectious respiratory adverse events in eight controlled trials [77];
on the contrary, a previous systematic review demonstrated an association between the appearance or
worsening of ILD and LEF. Bilateral ground-glass opacities and diffuse alveolar damage were the most
common radiologic and histopathologic findings of ILD secondary to leflunomide [78].
3.3. Azathioprine
In 1977, a case report described a patient with RA biopsy-proven ILD that improved after
azathioprine (AZA) administration [79]. More recently, two retrospective studies described RA-ILD-UIP
patients treated with corticosteroids and cDMARDs, including AZA, without conclusive results [46,65].
On the other hand, pulmonary toxicity has been also described for AZA [80]. In 2016, Oldham et al.
studied adverse events related to AZA in patients with fibrotic CTD-ILD, including 15 patients with
RA-ILD. Finally, AZA was compared with MMF, demonstrating a marginally better efficacy but a
higher rate of side effects [81].
3.4. Sulfasalazine, Hydroxychloroquine, and Penicillamine
Lung toxicity is a rare side effect of sulphasalazine. In the past decades, numerous case
reports have been published implicating sulphasalazine in acute lung toxicity, namely interstitial
pneumonitis and eosinophilic pneumonia. Many patients with suspected sulphasalazine-induced
lung disease improved within a few weeks after drug withdrawal [82]. No data are available
regarding the pulmonary toxicity of hydroxychloroquine. Although D-penicillamine could induce
acute hypersensitivity pneumonitis [83,84], its use in the treatment of RA-ILD has been also anecdotally
described [85].
3.5. Calcineurin Inhibitors (Cyclosporin, Tacrolimus)
Ciclosporin has been used in the treatment of RA-ILD with slight efficacy [46,86–89]. Some
case reports described improvement or stability of ILD in a total of four RA patients treated with
cyclosporin [80,86–88].
Tokano et al. describe a case series of 25 patients with various rheumatic diseases and
steroid-resistant ILD, treated with cyclosporin A. Of the four patients with a diagnosis of RA,
only one showed a transient response, while two patients died and the latter showed no response [89].
Tacrolimus has been successfully used in patients with ILD related to inflammatory myositis,
such as dermatomyositis and anti-synthetase syndrome, also when presenting as acute respiratory
distress syndrome [90–92].
In 2018, Yamano et al. treated 26 patients with ILD, including 11 with RA, with tacrolimus and
steroids. After a 12-month follow-up, PFTs and dyspnea significantly improved, without remarkable
life-threatening adverse events [48].
However, the use of calcineurin inhibitor is often limited by their side effects and their efficacy in
RA-ILD remains undefined and needs more dedicated studies (Table 3).
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Table 3. Pulmonary effects of immunosuppressants and conventional disease-modifying anti-rheumatic
drugs (cDMARDs) in RA-ILD patients: a review of the literature.
Cyclophosphamide
Number of patients 89
Author, year (Ref) Article type
Chang HK, 2002 [86] case report 1
Schupp JC, 2016 [57] retrospective study 7
Fu Q, 2018 [60] retrospective study 81
Other articles *
Song JW, 2013 [46] na 84
Zhang G, 2015 [56] na 23 CTD-ILD
Mycophenolate Mofetil
Number of patients 29
Author, year (Ref) Article type
Saketkoo LA, 2008 [63] case series 3
Fischer A, 2013 [62] retrospective study 18
Oldham JM, 2016 [81] retrospective study 8
Other articles *
Zhang G, 2015 [56] na 23 CTD-ILD
Methotrexate
Number of patients 72
Author, year (Ref) Article type
Rojas-Serrano J, 2012 [65] retrospective study 18
Rojas-Serrano J, 2017 [72] retrospective study 54
Leflunomide
Number of patients 12
Author, year (Ref) Article type
Rojas-Serrano J, 2012 [65] retrospective study 12
Azathioprine
Number of patients 27
Author, year (Ref) Article type
Cohen JM, 1977 [79] case report 1
Ishida T, 2012 [80] case report 1
Rojas-Serrano J, 2012 [65] retrospective study 10
Oldham JM, 2016 [81] retrospective study 15
Other articles *
Song JW, 2013 [46] na 84
Penicillamine
Number of patients 7
Author, year (Ref) Article type
van der Schee AC, 1989 [85] open trial 7
Cyclosporine
Number of patients 8
Author, year (Ref) Article type
Puttick MP, 1995 [88] case report 1
Ogawa D, 2000 [87] case report 1
Tokano Y, 2002 [89] pilot study 4
Chang HK, 2002 [86] case report 1
Ishida T, 2012 [80] case report 1
Other articles *
Song JW, 2013 [46] na 84
Tacrolimus
Number of patients 11
Author, year (Ref) Article type
Yamano Y, 2018 [48] retrospective case series 11
* Cumulative data on more diseases or drugs. Patients not included in the evaluation of lung outcome. Legend:
na = not available.
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4. Biological Disease-Modifying Antirheumatic Drugs (bDAMRDs)
Almost all of the bDMARDs have been associated with lung toxicity; however, their ability to
improve lung function and stabilize pulmonary symptoms have been also described [34–36].
The possible effectiveness of bDMARDs in RA-ILD has been described in only a few retrospective
studies and as anecdotical reports. Most of the available data in this field in current literature describe
the pulmonary effect of bDMARDs used for RA in patients with concomitant ILD.
4.1. Tumour Necrosis Factor Alpha Inhibitors
Tumour necrosis factor-alpha inhibitor (TNFi) may have both profibrotic and antifibrotic effects,
the imbalance between these two roles might trigger fibrosis or stabilize ILD [93–95].
In fact, transgenic mice over-expressing TNF-alpha develop interstitial pneumonitis resembling
IPF. TNF-alpha upregulates the expression of transforming growth factor-beta 1 in vitro and in
an animal model, resulting in chronic inflammation and lung fibrosis [93]; but, on the contrary,
the TNF-alpha supplementation ameliorates the lung function and architecture in TNF-alpha (−/−)
mice with bleomycin-induced lung fibrosis [95].
TNFi has been associated by many Authors to new onset or exacerbation of RA-ILD [96–104],
and the British Society of Rheumatology specifically cautioned prescribing TNFi to patients with
RA-ILD [105]. Recently, the NICE and Spanish Society of Rheumatology contraindicated TNFi in this
population [39,40]
Despite these observations, other studies confuted lung toxicity for TNFi and showed that
these drugs can stabilize or even improve pulmonary interstitial disease [34,106,107]. For example,
an American cohort study observed that, compared with cDMARDs, the use of TNFi did not increase
the occurrence of ILD among RA patients [106].
A British national prospective observational study of 367 patients with pre-existing RA-ILD found
that the mortality in patients with RA-ILD was not increased by treatment with TNFi compared with
cDMARDs. However, the proportion of deaths attributable to RA-ILD was higher in patients treated
with TNFi therapy (34%) [96].
Finally, in the only prospective study available, Detorakis evaluated, in RA patients with or
without ILD, the effects of TNFi on lung parameters, observing that the ILD extent score remained
unchanged both in the TNFi and cDMARDs groups. There was no exacerbation of ILD, nor new ILD
onset in patients without pre-existing ILD. Moreover, TNFi induced an improvement of small airways
disease [108].
On the contrary, Nakashita described a potentially negative role of TNFi in RA-ILD patients.
He described 14 interstitial disease events on 46 RA-ILD patients treated with TNFi; among them,
four patients developed generalized lung disease and two died from ILD progression [109]. The same
Authors did not observe an increase in the prevalence of ILD progression in patients treated with
tocilizumab and abatacept, whereas prevalence of 3% of new ILD appearance and 24% of ILD worsening
were described in TNFi users [109].
Curtis did not find significant differences in the risk of ILD and its related complications among
RA patients treated with a second-line biologic therapy after TNFi, comparing second-line TNFi agents
or bDMARDs with other mechanisms of action [110].
4.1.1. Infliximab
Only a few case reports describe the positive effect of infliximab on RA-ILD. Vassallo described an
improvement of dyspnea and stabilization of PFTs in a patient with RA-ILD refractory to corticosteroid,
after 12 months of infliximab treatment [107]. Bargagli reported another similar case in 2004 [111],
while Antoniou et al. identified a good response to infliximab in a case series of three previously
progressive RA-ILD patients [112].
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Otherwise, there are many reports about the possible iatrogenic role of infliximab in the
development or exacerbation of RA related ILD [97,101]. In a post-marketing surveillance study in
Japanese RA patients, interstitial pneumonitis was observed in 25 patients (0.5%), after a mean of
2.8 infusions of infliximab [103] and respiratory disorders were the most common serious adverse
drug reactions.
4.1.2. Adalimumab
As for the other TNFi, data was derived by post-marketing surveillance reports. The Japan
College of Rheumatology, on 3000 RA patients treated with adalimumab, described the occurrence
of interstitial pneumonia in 0.6% of patients [98]. In another retrospective Japanese study on 200 RA
patients treated with adalimumab, respiratory disorders were the third most common adverse event,
represented by interstitial lung lesions in three patients and organizing pneumonia in two [113].
A case report in 2011, described conflicting actions of adalimumab in the same patient with
RA-ILD, suggesting that the drug might be effective against RA-ILD, but may also have caused
drug-induced ILD [114]. Case reports also describe an anecdotal association between ILD and the use
of adalimumab [115,116].
4.1.3. Etanercept
Etanercept has been evaluated in a randomized controlled trial in the treatment of IPF, but without
obtaining significant differences from placebo in disease progression nor the change of predicted FVC
from baseline [117].
Only two case reports described possible effectiveness of etanercept in females with
RA-ILD [118,119]. In the first, treatment with etanercept improved symptoms and physical capacities
in a girl with juvenile chronic arthritis and pulmonary interstitial disease [118]. More recently,
Wang et al. described a sustained improvement in symptoms, PFTs, and high-resolution computer
tomography (HRCT) findings after etanercept treatment in a 52-year-old woman with RA-ILD refractory
to corticosteroids and azathioprine [119].
In 2012, a short review described 12 RA-ILD patients treated with etanercept, six with pre-existing
ILD and six with newly-diagnosed ILD. Among them, eight patients developed a severe ILD (without
concomitant use of MTX) and two patients died [120].
Moreover, exacerbation of pre-existing ILD during etanercept therapy in RA patients was
described [121–123]. In a real-life surveillance report published in 2011, among 13,894 patients, the most
frequent serious adverse events were pneumonia (0.8%) and interstitial lung disease (n = 77, 0.6%) [124].
Two years later, the same Authors observed that etanercept in association with MTX showed significantly
lower incidence rates for total adverse events, including ILD, than etanercept alone or associated with
DMARDs different to MTX [125].
4.1.4. Golimumab and Certolizumab
No reports are describing the use of certolizumab or golimumab in the treatment of RA-ILD
patients, but, on the contrary, a possible relationship between these drugs and new-onset or acute
exacerbation (AE) of ILD has been described [100,126–129]. In 2017, a post-marketing surveillance
study from 2579 Japanese patients treated with certolizumab reported an event rate of ILD of 1.22 per
100 patient-year (Table 4 and Figure 1) [130].
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Table 4. Pulmonary effects of TNFi in RA-ILD patients: a review of the literature.
TNF Alpha Inhibitors
Number of patients 96
Improvement 47 48.4%
Stability 35 36.1%
Worsening 15 15.5%
Author, year (Ref) Article type
Schultz R, 2001 [118] case report 1
Vassallo R, 2002 [107] case report 1
Bargagli E, 2004 [111] case report 1
Antoniou KM, 2007 [112] prospective case series 3
Wang Y, 2011 [119] case report 1
Komiya K, 2011 [114] case report 1
Nakashita T, 2014 [109] retrospective review 46
Detorakis EE, 2017 [108] prospective study 42
Other articles *
Kurata I, 2019 [131] retrospective study 30
* Cumulative data on more diseases or drugs. Patients not included for the evaluation of lung outcome.
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4.2. Abatacept
Increasing interest in abat cept in RA-ILD is eme ging in the last years. In a murine model,
abatacept (ABA) significantly reduced fibrogenic marker levels, T-cell proliferation, and M1/M2
macrophage infiltration in the lungs of Fra-2 mouse model, characterized by ILD and pulmonary
vascular remodeling leading to pulmonary hypertension [132]. Moreover, ABA improved ILD,
significantly reducing the lung density on chest HRCT and fibrosis histological score [133].
In 2014, Mera-Valera et al. used ABA in a case series of four RA-ILD patients, observing no
adverse events nor deterioration of respiratory function tests [134]. Howeve , in a previous case
report, ILD worsened two days after the administration of ABA and subsequently improved after
drug discontinuation in a 55-year-old man enrolled in a trial of phase III of ABA in Japan. Interstitial
shadows worsened on HRCT scans taken on day 13, nd the pa i nt withdrew from the trial. [135].
Ye used corticosteroids and ABA to control both joint and pulmonary disease in a RA patient who
developed ILD during treatment with rituximab and MTX. The PFTs parameters improved despite a
reduction of the st oid d se to 5 mg d ily. [136].
Nowadays, there are six retrospective studies that investigate the role of ABA in patients
with RA-ILD.
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Nakashita retrospectively evaluated the effectiveness and safety of abatacept in 16 RA-ILD patients.
None of them experienced a worsening of ILD after one year, while two patients showed complete
resolution of the pulmonary lesions [137].
As reported above, in 2015, Curtis et al. evaluated the incidence of ILD and the risk of
hospitalization in a large cohort of RA patients exposed to TNFi or other biologic drugs. They found
no significant differences in the risk of ILD and its related complications between patients exposed to
tocilizumab, rituximab, or abatacept compared with TNFi therapies [110].
In a Spanish, retrospective, multicenter, non-controlled study on 63 RA patients with ILD treated
with ABA, two-thirds of them remained stable, while one-quarter experienced improvement of the
dyspnea after a mean follow-up of 9.4 ± 3.2 months. In the meantime, FVC remained stable in
almost two-thirds of patents and improved in one out of five patients assessed. Additionally, DLCO
remained stable in almost two-thirds and showed improvement in a quarter of the patients assessed.
At 12 months, ILD was stable at HRCT in 11/22 patients in whom a chest scan was performed, improved
in eight and worsened in three [138].
Mochizuki T. showed deterioration of ILD in 8.4% of 131 RA patients treated with ABA for at least
one year. On the other hand, ILD improved in 14.5% of 55 patients with ILD at baseline. Worsening of
ILD was associated with the concomitant use of MTX at multivariate logistic regression analysis. [139].
Recently, Kurata et al. evaluated the association between different bDMARDs and new-onset or
worsening of RA-airway disease and RA-ILD. Pre-existing airway disease was an independent risk
factor for ILD exacerbation or appearance after the start of bDMARDs, namely TNFi, tocilizumab,
and ABA. Moreover, ABA was an independent protective factor for RA-ILD exacerbation [131].
Finally, in 2020, we published data from a retrospective multicenter Italian study evaluating the
evolution of ILD in 44 Italian RA-ILD patients treated with abatacept for at least six months. FVC and
DLCO remained stable or increased in 86.1% and 91.7% of patients, respectively, while HRCT was
stable or improved in 81.4% of them. Previous and concurrent treatments, serology, age, sex, joint and
lung disease duration were not associated with the outcome at univariate analysis [140].
Of interest, a preliminary small clinical trial is ongoing to assess the feasibility of a larger controlled
study to evaluate the safety of ABA in RA-ILD (APRIL study, NCT03084419) (Table 5 and Figure 2).
Table 5. Pulmonary effects of abatacept in RA-ILD patients: a review of the literature.
Abatacept
Number of patients 187
Improvement 31 16.6%
Stability 140 74.9%
Worsening 16 8.5%
Author, year (Ref) Article type
Wada T, 2012 [135] case report 1
Mera-Varela A, 2014 [134] case series 4
Nakashita T, 2014 [109] retrospective review 3
Nakashita T, 2016 [137] retrospective study 16
Ye W, 2017 [136] case report 1
Fernández-Díaz C, 2018 [138] retrospective study 63
Mochizuki T, 2019 [139] retrospective study 55
Cassone G, 2020 [140] retrospective study 44
Other articles *
Kurata I, 2019 [131] retrospective study 12
* Cumulative data on more diseases or drugs. Patients not included in the evaluation of lung outcome.
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4.3. Interleukin-6 Inhibitors
4.3.1. Tocilizumab
The proinflammatory cytokine IL-6 shows profibrotic effects antagonizable by IL-6R blockade [141],
suggesting a potential benefit of this therapeutic strategy in RA-as ociat d pulmonary fibrosis. Anyway,
data on its use in RA-ILD is anecdotal and conflicting.
For example, tocilizumab (TCZ) as monotherapy was found to stabilize or even improve ILD in a
case-series of four RA patients, [142] a d two previous case reports described similar observations [143,144].
Improvement or stabilization of lung function in 75% of cases was described also in a retrospective
national multicenter study of 28 RA-ILD patients treated with TCZ with or without MTX [145].
On the other hand, adverse lung effects have bee also re orted after the use of TCZ. In particular,
Wendling described the worsening of pre-existing ILD in a patient after 23 infusions of TCZ as
monotherapy and subsequent improvement of symptoms and HRCT findings after its withdrawal [146].
Moreover, other reports correlate T with AE of pre-existing interstitial lung disease, even with
fatal outcome [147,148]. The retr spective case-control study by Akiyama et al. aimed to identify risk
factors for AE of ILD during TCZ treatment in patients with RA. Of 78 patients, six developed AE.
Univariate analysis showed that only disease activity was a risk factor for AE. [148].
Data from real-life post-marketing surv illance show a good s fety profil for TCZ in a Japanese
population of RA-ILD patients [149,150].
In an interim analysis, the presence of ILD was a risk factor for AE and serious infections [149].
In 2014, am ng 7901 patients, ILD was recorded in 38 (22 patients had ILD at baseline, while 16
developed ILD during treatment). Twenty-four of 38 patients had previously received other biologics.
Of the 38 patients, 14 improved, 12 recovered and seven died. In a multivariate logistic regression
analysis, the risk factors for ILD deteriorati n were advanced age (≥65 years) and previous or concurrent
ILD at baseline [150].
Of interest, the incidence rate of ILD (0.5%) found in Japan for TCZ was similar to that recorded
for infliximab (0.5%), adalimumab (0.6%), and etanercept (0.6%) (Table 6 and Figure 3) [98,103,124].
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Table 6. Pulmonary effects of tocilizumab in RA-ILD patients: a review of the literature.
Tocilizumab
Number of patients 41
Improvement 7 17.0%
Stability 27 65.8%
Worsening 7 17.0%
Author, year (Ref) Article type
Mohr M, 2011 [144] case report 1
Wendling D, 2013 [146] case report 1
Nakashita T, 2014 [109] retrospective review 9
Picchianti Diamanti A, 2017 [143] case report 1
Manfredi A, 2018 [142] case series 4
Manfredi A, 2019 [145] retrospective study 28
Other articles *
Koike T, 2014 [150] Post-marketing data 22
Kurata I, 2019 [131] retrospective study 7
* Cumulative data on more diseases or drugs. Patients not included in the evaluation of lung outcome.
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analysis of biological therapies in CTD noted that RTX was associated with an increase of non-
infectious parenchymal lung disease [156]. Furthermore, lung toxicity is widely described for RTX in 
hematological patients [156–160]. 
In a prospective study of 33 RA patients, the use of RTX resulted in a DLCO decline in 22% of 
the patients. Even if no cases of symptomatic lung injury were observed, the progressive DLCO 
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4.3.2. Sarilumab
No new o set of ILD was described in RA pati nts treated with sarilumab during pre-marketing
clinical trials. However, all the enrolled patients were evaluated for the presence of lung disease and a
pre-existing ILD was considered as an exclusion criterion.
4.4. Rituximab
According to some retrospective data e anecdotal case reports [151–154], rituximab (RTX) is usually
considered a safe ther py for ILD including severe refractory forms [155]. However, a meta-analysis
of biological therapies in CTD noted that RTX was associated with an increase of non-infectious
parenchymal lung disease [156]. Furthermore, lung toxicity is widely described for RTX in hematological
patients [156–160].
In a prospective study of 33 RA patients, the use of RTX resulted in a DLCO decline in 22% of the
patients. Even if no cases of symptomatic lung injury were observed, the progressive DLCO decline
suggested the presence of subclinical RTX-induced pulmonary toxicity [161].
In 2012, Hartung et al. firstly described a 66-year-old patient with severe RA-ILD successfully
treated with RTX after the failure of prednisolone and CYC [153].
In the retrospective study by Keir et al., 33 patients received RTX for ILD related to CTD, two of
them with RA. The Authors concluded that RTX may be an effective therapeutic option in these cases,
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even if the highest proportion of patients with a categorical improvement was seen in the group with
IIM. Data on RA patients cannot be deduced [162].
In 2019, Duarte et al. described 17 RA-ILD patients treated with RTX. After a 12-month follow-up,
all patients with OP or NSIP (n = 12) demonstrated improvement or stability of PFTs and HRCT.
Regarding patients with UIP pattern, 2/3 of patients had a decline in FVC and half had HRCT
worsening [15].
Moreover, Chartrand described a highly variable response in the clinical status of 15 RA-ILD
patients, without significant variations of FVC over time nor a corticosteroid-sparing effect [163].
A 10-year study by Yusof et al. assessed the effects of RTX in 700 RA patients, of whom 56 (8%)
had a previous diagnosis of ILD and 44 had data on lung function; pulmonary involvement improved
or remained stable in 68% of cases, while 18 patients (32%) showed a progression of ILD and half of
them (16%) died because of progressive ILD. Factors associated with ILD progression were radiologic
UIP pattern, a previous history of lung progression, and DLCO < 46% predicted before the therapy.
During the follow-up period, only three patients developed incident cases of RA-ILD (incidence of
0.4%) [154].
In 2017, Druce et al. retrospectively analyzed 352 patients with RA-ILD treated with either RTX or
TNFi as first-line biologic therapy, observing no differences in survival and cause of death between the
two groups [152].
In 2019, Fui et al., in another retrospective study on 14 RA-ILD patients, observed a possible effect
of RTX in reducing lung function deterioration after 6 and 12 months [164].
On the contrary, Matteson showed improvement of ILD only in 1/10 RA-ILD patients treated
with RTX in an open-label pilot study [165]. Finally, Becerra et al. didn’t experience respiratory
improvement in 19 patients with established RA-ILD over four years, and 15 patients (66%) reported
respiratory infections. [166].
A high rate of side effects was reported also by Dass in 48 patients with RA-ILD treated with RTX:
three patients died, one because of pneumonia and possible acute progression of ILD. Five patients had
a decline of DLCO > 10%. [167]. In another abstract, 53 patients with RA-ILD treated with RTX were
analyzed. There was no substantive or significant reduction in FVC and DLCO over time; 11 patients
received also CYC. Only three patients were diagnosed with new ILD after RTX. Nine patients died
because of progressive ILD (Table 7 and Figure 4) [168].
Table 7. Pulmonary effects of rituximab in RA-ILD patients: a review of the literature.
Rituximab
Number of patients 201
Improvement 11 5.4%
Stability 154 76.6%
Worsening 34 16.9%
Author, year (Ref) Article type
Dass S, 2011 [167] abstract 48
Matteson EL, 2012 [165] open-label pilot study 7
Hartung W, 2012 [153] case report 1
Kabia A, 2015 [168] abstract 53
Chartrand S, 2016 [163] case series 15
Yusof, 2017 [154] retrospectiveobservational study 44
Fui A, 2019 [164] retrospective study 14
Duarte AC, 2019 [15] retrospective study 17
Other articles *
Becerra E, 2012 [166] abstract 19
Keir GJ, 2014 [162] retrospective study 2
* Cumulative data on more diseases or drugs. Patients not included in the evaluation of lung outcome.
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5. Targeted Synthetic Disease-Modifying Antirheumatic Drugs (tsDMARDs)
Tofacitinib and baricitinib have been recently licensed for the treatment of RA. Tofacitinib
selectively inhibits the janus-kinase (JAK) 1 and 3, while baricitinib blocks JAK1 and JAK2 pathways.
Data regarding the relationship between JAK inhibitors and RA-ILD in real life are limited [169].
In RA clinical development programs of tofacitinib and baricitinib, 0.1% of he p tients developed
ILD and some of them were de novo ILD [170,171].
Successful use of tofacitinib has recently been described for ILD associated with anti–melanoma
differentiati n–associated protein 5 (anti-MDA5)–posit ve amy pa h c derma omyositis [172,173].
Phase III trials of tofacitinib in combination with MTX have reported only a few cases of new-onset
ILD and pulmonary sarcoidosis [174], and a combination of pulmonary fibrosis and chronic obstructive
pulmonary di ase have been obse ved in trials using tof citinib as monotherapy [175].
A very low rate of ILD was recorded in the open-label extension of pre-marketing trials and in the
post-marketing surveillance of tofacitinib: 18/2631 patients developed ILD in combination therapy
with MTX and 9/1543 in monotherapy in the open-label extension of clinical trials and 15 cases on
34,223 patients/year in post-marketing surveillance, respectively [176,177]. An interim analysis of the
Japanese post-marketing surveillance program of tofacitinib identified 14 cases (0.5%) with serious
ILD, of which three died [178].
In three RA-ILD patients, tofacitinib was able to treat joint involvement with t e stability of lung
function and without pulmonary adverse events [179].
Recently, tofacitinib demonstrated its ability to facilitate the expansion of myeloid-derived
suppressor cells (MDSC) and ameliorate arthritis in SKG mice, a murine model developing not only
arthritis but also ILD. In SKG mice, tofacitinib significantly suppressed the progression of ILD compared
to control, by increasing myeloid-derived suppressor cells and suppressing Th17 cells proliferation
and differentiation [180]. On the contrary, in another in vitro study, the JAK2 inhibition, but not the
selective JAK1/JAK3 pathway, significantly reduced IL-17A-induced fibrogenic response in RA-ILD
patients [181].
6. Antifibrotic Agents
RA-ILD shares some similarities with IPF, especially in patients with a UIP pattern. It shows a
similar clinical behavior, often with a progressive fibrosing phenotype, and a comparable prognosis
and survival [33]. Some authors suggest that RA-ILD and IPF might also overlap in disease
pathogenesis [182].
Moreover, genetic risk factors, previously well characterized in IPF, are increasingly being linked to
RA-ILD. For example, the MUC5B promoter variant rs5705950, telomerase complex mutations, and short
telomere lengths are also linked to an increased susceptibility to UIP pattern in RA-ILD [33,183,184].
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The parallelisms between UIP in RA-ILD and IPF may suggest a plausible rationale in the use
of antifibrotic therapy in these patients to treat the fibrotic process, improve outcomes and reduce
lung disease progression. Moreover, given both the fibrotic and inflammatory components of this
systemic disease, the combination of immunosuppressive and antifibrotic treatment can potentially be
a possible future approach to this spectrum of the disease.
The INBUILD trial recently assessed the efficacy and safety of nintedanib in patients with a
diagnosis of ILD other than IPF, including RA [185]. Moreover, several trials are planned or ongoing to
assess the efficacy and safety of antifibrotic agents in the treatment of fibrosing ILDs other than IPF,
including patients with RA (Table 8) [185–188].
Table 8. Clinical trials of antifibrotic agents for the treatment of fibrosing ILDs other than IPF, including
patients with RA.
Trial Number
(Ref)
Study
Name Phase, Design, Population Patients Duration State
NCT02999178
(extension
NCT03820726)
[185]
Inbuild
Phase III
efficacy and safety of nintedanib
in patients with PF-ILD
663 52 w
Completed
Extension
in fieri
EudraCT
2014–000861-32
DRKS00009822
[186]
Relief
Phase II
Efficacy and safety of pirfenidone
as an add-on to existing treatment
for progressive, non-IPF lung fibrosis
374 48 w Completed
NCT02808871
[187] Trail1
Phase II
Efficacy and safety of pirfenidone
as an add-on to existing treatment
in patients with RA-ILD
270
estimated 52 w Recruiting
NCT03843892
[188] na
Expanded access program to provide
nintedanib
to patients with non-IPF ILD who have
no alternative treatment possibilities
na na Available
Legend: na = not available.
6.1. Pirfenidone
In Europe, pirfenidone is approved for the treatment of IPF [189].
Interestingly, Pirfenidone reduces the levels of IL6 and TNF-alpha, both cytokines related to the
activation of macrophages and with a proven role in RA pathogenesis [190]. Recently, it also showed
an inhibitory effect on fibroblast to myofibroblast transition in RA-ILD [191].
Pirfenidone is currently under investigation in patients with RA-ILD (TRAIL1) [187]. This phase
II study (NCT02808871) estimates to enroll 270 RA-ILD patients to treat with pirfenidone three times
daily (2403 mg) as an add-on to existing treatment. It will evaluate a composite primary end-point with
PFTs (≥10% decline in FVC or death) and other secondary outcomes (relative decline in DLCO, FVC,
the incidence of AE, dyspnea scores, safety, and tolerability). No preliminary data are available yet.
6.2. Nintedanib
Nintedanib is approved for the treatment of IPF, it has been shown to slow down the decrease in
FVC and to reduce the number of AE [189]. In vitro, nintedanib demonstrated its efficacy in reducing
both pulmonary fibrosis and joint disease in female SKG mice with RA [192].
Recently, interesting results have been observed in the INBUILD study. This double-blind,
placebo-controlled, phase 3 trial aimed to evaluate the efficacy and safety of nintedanib in progressive
fibrosing ILD secondary to other conditions than IPF. The most frequent diagnoses were chronic
hypersensitivity pneumonitis (26.1%) and autoimmune ILD (25.6%), including also RA-ILD patients.
The patients who received nintedanib had a slower annual rate decline of FVC over a 52-week period
in ILD than placebo. Of interest, the results were similar in patients with UIP-like fibrotic pattern or
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other radiological/histological patterns. However, data on specific diseases associated with ILD are not
still available [185].
In 2018, a first case report described a 74-year-old man diagnosed with RA-ILD (UIP pattern)
treated with nintedanib. The use of nintedanib resulted in decreased coughing together with a
reduction in FVC decline, from −11.6%/year to −5.2%/year. [193].
7. Conservative Therapy
Conservative treatment may be advisable for patients with a mild and non-progressive disease
or contraindications to pharmacological treatments, such as multiple comorbidities, advanced age
or frailty syndrome. Non-pharmacological treatments usually include pulmonary rehabilitation,
psychological and educational support.
7.1. Smoking Cessation
Cigarette smoke is implicated in the pathogenesis of RA-ILD, but also in inducing and worsening
both the severity of articular disease and lung damage. Additionally, much evidence suggests
that smoking reduces the drug response and survival in RA patients. In particular, some studies
demonstrated a poorer response to TNFi and a reduced chance of achieving low disease activity for
heavy smokers, especially for infliximab. Both smoking status and pack-year history at the start of
therapy have been associated with a low response to treatment [194].
On the contrary, more recently the CIMDORA study did not find any correlation between cigarette
smoking and the effectiveness of certolizumab pegol in 218 RA patients [195].
Finally, a recent metaanalysis found no high-quality studies that investigate the evidence of the
effects of smoking cessation on disease activity in RA patients [196].
However, given its well-established role in the development of RA and pulmonary toxicity and
its association with the severity of the diseases, smoking cessation should be strongly encouraged.
The support of anti-smoking counseling centers and the possible use of nicotinic replacement therapy
should be considered in all patients with RA.
7.2. Pulmonary Rehabilitation
The usefulness of pulmonary physical rehabilitation in RA-ILD is yet undefined. However,
in idiopathic ILD, it has a short-term beneficial effect on dyspnea, functional exercise capacity, and quality
of life [197,198]. However, in RA-ILD patients, pulmonary rehabilitation may be compromised by the
functional joint limitations related to the underlying disease.
7.3. Oxygen Supplementation
Oxygen supplementation can be a major palliative therapy to improve the quality of life in patients
with severe lung disease, reducing respiratory symptoms during daily activities.
No data directly address the use of long-term oxygen supplementation in patients with IPF
or RA-ILD.
7.4. Vaccination
Corticosteroids and immunosuppressants, as well as the presence of ILD, are associated with a
high risk of serious infection in RA patients [49,50].
Influenza and anti-pneumococcal vaccines should be proposed for all RA patients. Some Authors
also recommend prophylaxis against pneumonia by Pneumocystis Jirovecii for all patients in
immunosuppressive therapy [3].
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7.5. Comorbidities
Specific treatment is recommended in case of comorbidities that can worsen the clinical course of
the disease, for example, pulmonary hypertension, chronic obstructive pulmonary disease (COPD),
gastro-oesophageal reflux, and sleep apnoea.
In particular, COPD can be associated with ILD in smokers or former smokers and it can determine
the presence of mixed histological/radiological patterns (Table 2), such as “combined pulmonary
fibrosis and emphysema” (CPFE). Patients with CPFE often have a low DLCO and a higher risk for
pulmonary hypertension and lung malignancy [199].
In IPF and RA-ILD patients, Antoniou et al. found that emphysema was associated with lower
pack-year smoking histories than in control groups and with coarser pulmonary fibrosis, suggesting a
possible pathogenetic link with smoking for both diseases [200]. No data are available regarding the
response to therapy in CPFE subtype of RA-ILD. Finally, COPD could increase the infective risk in
patients treated with conventional or biologic DMARDs [50].
8. Lung Transplant
Lung transplantation may be an option in end-stage RA-ILD. However, there are few studies
evaluating post-transplant outcomes in RA-ILD patients. The survival rates of 10 patients with RA-ILD
who had undergone lung transplantation were similar to patients with IPF [201].
In ILD related to CTD or RA, other extrapulmonary disease manifestations may complicate or
contraindicate transplant procedures.
Recently, in a Northern Spanish study, CTD-ILD patients (including RA) showed a lower frequency
of acute graft rejection than IPF, but also a lower 5-year cumulative survival rate [202].
Finally, a retrospective cohort compared survival, acute and chronic rejection, and extrapulmonary
organ dysfunction after transplantation in patients with non-scleroderma connective tissue-related lung
disease (NS-CTLD) (including RA) and IPF. The Authors found no significance between NS-CTLD and
IPF. So, in appropriately selected candidates, NS-CTLD should not be considered a contraindication to
lung transplantation [203].
9. Acute Exacerbation of Ra-Ild
Acute exacerbation (AE) is a life-threatening condition defined as rapidly deteriorating respiratory
symptoms within a 1-month period with newly developed bilateral ground-glass opacities and/or
consolidations on chest CT scans, superimposed on a background pattern consistent with fibrosing
ILD [204]. Other than IPF, AE can also complicate secondary forms of ILD, such as RA, CTD, and chronic
hypersensitivity pneumonia [205–211].
In RA-ILD patients, older age at ILD diagnosis, UIP pattern, and MTX have been reported as the
major risk factors for AE development [212]. AE of RA-ILD can occur at any time during the disease,
and occasionally it can represent the onset manifestation of ILD [205–211]. It has a poor prognosis and
high mortality, similar to AE in IPF. Therefore, early diagnosis and referral might be important for the
patient’s prognosis.
Currently, there is no evidence-based data on effective therapies in AE-ILD. Usually, corticosteroid
therapy is empirically used, with or without immunosuppressive agents and antibiotics. [205–211,213–215].
Ota et al. [214] retrospectively reviewed 12 RA-ILD patients with AE treated with corticosteroids.
Tacrolimus was added in three cases, cyclosporine in four and CYC in another five patients. Pulmonary
function and HRCT alterations significantly improved in all cases but the CYC group had a better life
prognosis, while two patients in the cyclosporine group and one patient treated with corticosteroids
alone died for a relapse of AE.
Toyoda retrospectively reviewed 10 patients with CTD-ILD and AE, including six RA-patients.
All patients were treated with antimicrobial agents and high dose corticosteroids, whereas CYC or
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tacrolimus was added only when a poor response to corticosteroids was observed. The median survival
time after onset AE was significantly longer in patients treated with corticosteroids only [209].
In 2019, we investigated the incidence of AE in a population of patients with CTD-ILD; in this
context, two patients with RA and AE were enrolled and treated with a high dose of corticosteroids:
one patient died while the other survived [211].
Finally, two patients with AE successfully treated with nintedanib without corticosteroids or
immunosuppressants have been described [215,216].
10. Biomarkers and Response to Treatment
Although there are some contrasting data, many biomarkers have been investigated as possible
predictors of appearance or progression of lung involvement in RA [217]. In particular, Krebs von
den Lungen 6 (KL-6) could reflect the severity of ILD as assessed through HRCT and PFT parameters.
Its potential role has been evaluated prevalently in Asian patients both in diagnosis and monitoring
lung involvement [217,218]; a high value of KL-6 has been associated with mortality and usual
interstitial pneumonia (UIP) pattern at HRCT [218]. Moreover, an increase of KL-6 has been associated
with a progression of ILD over time as a possible marker of treatment response [139,219].
Many other biomarkers have been evaluated in RA-ILD, such as matrix metalloproteinase
7 (MMP-7), pulmonary and activation-regulated chemokine, and surfactant protein D (SP-D).
In 113 RA patients, a combination of age, sex, smoking, rheumatoid factor, and anticyclic citrullinated
peptide antibodies was strongly associated with RA-ILD; the inclusion of MMP-7, pulmonary and
activation-regulated chemokine, and SP-D significantly increased the areas under the curve from
0.88 to 0.97 for the identification of patients with ILD. Interstingly, similar trends were seen for both
clinically evident and subclinical RA-ILD [220].
Finally, a specificity of 90% for RA-ILD has been reported by Harlow for serum autoantibodies
targeting citrullinated heat shock protein 90 alpha (Hsp90α) or beta (Hsp90β) [221].
11. Proposal for Patient Management and Treatment
The optimal therapeutic regimen of RA-ILD has not been determined as no large randomized
controlled trials are yet available.
Treatment options for RA-ILD are further complicated by the implication of almost all drugs
used for RA in pulmonary toxicity, and the lack of evidence for their efficacy in the treatment of ILD.
Moreover, immunosuppressive drugs employed in CTD or antifibrotic drugs approved for IPF are not
effective on the articular manifestation of the disease.
Furthermore, the substantial variability in RA-ILD clinical presentation (subclinical, progressive,
slow progression, non-progressive, chronic, acute exacerbation, etc.), histopathologic subtypes,
and disease course make it difficult to speculate about one milestone therapeutic approach.
Therefore, the development of guidelines for RA-ILD treatment remains an open challenge.
The treatment of RA-associated ILD should be tailored for each patient after the evaluation of:
- age, gender, comorbidities;
- progression and severity of the lung involvement (symptoms, PFTs, DLCO, HRCT);
- histopathologic or HRCT pattern of ILD;
- activity and severity of joint disease;
- other extra-articular manifestations.
A multidisciplinary approach, including at least a rheumatologist, pulmonologist, and radiologist,
is necessary to optimize therapy and follow-up strategies. A multidisciplinary evaluation has been
confirmed as having a high level of confidence in particular for the diagnosis of IPF and CTD-ILD
including RA-ILD [222].
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Moreover, all RA patients should be considered at risk for ILD and the evaluation of lung
involvement during the routine clinical assessment is mandatory. Indeed, an early diagnosis is needful
to ensure that each patient receives appropriate treatment for their particular clinical phenotype and to
avoid the use of drugs potentially involved in ILD worsening. In this regard, we recently proposed
the use of VECTOR as a simple, non-invasive and inexpensive tool for the screening of RA patients
suspected for ILD [223].
A tight follow-up must be recommended in RA-ILD patients, utilizing periodic assessment of
respiratory symptoms, PFTs, DLCO and HRCT.
In patients with active joint disease and subclinical non-progressive ILD, current therapy with
DMARDs (including MTX and TNFi) should be continued to achieve low disease activity; while
in patients starting a new DMARD, the use of ABA, JAK inhibitors, IL6 inhibitors or RTX could
be appropriate [39,40,109]. However, we caution about the use of RTX in patients at a high risk of
infections of the lower respiratory tract [49,50,166]. The association with MTX should be evaluated in
every single patient.
In patients with progressive lung disease and mild articular involvement, immunosuppressants,
such as CYC and MMF, should be considered [51–56,61–64]. On the other hand, the recent data about
nintedanib allow us to suppose the future use of antifibrotic agents in ILD secondary to RA [185].
Finally, in patients with progressive ILD and active joint disease, combination therapy with
antifibrotic agents and bDMARDs could represent an interesting future research field (Figure 5).
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Figure 5. Proposed framework for the management and treatment of RA-ILD patients. Therapeutic
choice in patients with RA-ILD should derive by a multidisciplinary appr ach including a
rheumatologist, pulmonologist, and radiologist. Use of DMARDs (mainly ABA, JAK inhibitors,
IL6 inhibitors or RTX) should be evaluated according to the joint disease activity, while the progression
of lung involvement and, possibly ILD pattern, can influence the decision to use immunosuppressants
or, in selected patients, an antifibrotic drug.
J. Clin. Med. 2020, 9, 1082 22 of 35
12. Conclusions and Research Agenda
ILD is one of the most common extra-articular manifestations of RA, and its management
is challenging, for the deterioration of quality of life, the high mortality, and utilization of
healthcare resources.
Unfortunately, ILD is often underrated, particularly in its early and subclinical stages, and the
majority of available studies on this topic are retrospective and based on low-quality data.
The real epidemiology of ILD in RA patients is unknown, and no proteomic or serologic
biomarkers are available to improve our armamentarium for both diagnostic and prognostic purposes.
Non-homogeneous and sometimes discordant results regarding risk factors for RA-ILD have been
described and, finally, randomized controlled clinical trials to support therapeutic decisions in RA-ILD
patients are still missing.
In summary, there is an urgent need for prospective studies to clarify these crucial points in the
field of RA-ILD.
In this framework, possible future directions of research include the prognostic value of sub-clinical
RA-ILD; the development of screening programs to achieve early diagnosis of RA-ILD; prospective
studies to discover biomarkers and predictors of lung involvement in RA.
Moreover, well-designed therapeutic trials are mandatory, and future research could move to more
personalized management and treatment of RA-ILD patients, for example, to evaluate the possible
concomitant use of DMARDs and anti-fibrotic agents.
Recently, antifibrotic medications are supposed to have relevance across various ILD subtypes,
not only in the UIP pattern (INBUILD). Ongoing clinical trials in patients with non-IPF fibrosing
ILDs [185–188,224–227] and RA-ILD patients [185–188] (Table 8) will provide valuable insights into
the progression of these diseases in well-characterized populations.
Finally, the cooperation between multidisciplinary groups with different experiences may be
advisable for further well-designed studies on this topic. Efforts to develop a research network
comprising dedicated centers with both respiratory and rheumatology interest in RA-ILD should also
be made to deliver important new knowledge of this condition.
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Abbreviations
ABA ABATACEPT
AE Acute exacerbation
ANTI-MDA5 Anti–melanoma differentiation–associated protein 5
AZA Azathioprine
BDMARDS Biologic disease modifying anti-rheumatic drugs
CDMARDS Conventional disease modifying anti-rheumatic drugs
COPD Chronic obstructive pulmonary disease
CTD Connective tissue diseases
CTD-ILD Connective tissue diseases-realated interstitial lung disease
CYC Cyclophosphamide
DLCO Diffusing capacity of the lungs for carbon monoxide
DMARDS Disease modifying anti-rheumatic drugs
FVC Forced vital capacity
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HRCT High-resolution computer tomography
ILD Interstitial lung disease
IPF Idiopathic pulmonary fibrosis
JAK Janus-kinase
LEF Leflunomide
MDA5 Melanoma differentiation–associated protein 5
MDSC Myeloid-derived suppressor cells
MMF Mycophenolate mofetil
MTX Methotrexate
NICE National Institute for Health and Care Excellence
NS-CTLD Non-scleroderma connective tissue-related lung disease
NSIP Nonspecific interstitial pneumonia
OP Organizing pneumonia
PFTS Pulmonary function tests
RA Rheumatoid arthritis
RA-ILD Rheumatoid arthritis-related interstitial lung disease
RTX Rituximab
SSC-ILD Systemic sclerosis-related interstitial lung disease
TCZ Tocilizumab
TNFI Tumour necrosis factor alpha inhibitor
TSDMARDS Targeted synthetic disease modifying anti-rheumatic drugs
UIP Usual interstitial pneumonia
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